<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03687112</url>
  </required_header>
  <id_info>
    <org_study_id>18-DSP-03</org_study_id>
    <nct_id>NCT03687112</nct_id>
  </id_info>
  <brief_title>National Bank Alzheimer</brief_title>
  <acronym>BNA</acronym>
  <official_title>National Bank Alzheimer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Alzheimer's disease (MY) is a major problem of public health. The French National
      Database Alzheimer ( BNA) registers(records) all the medical acts made by units of
      memory(report) and of independent specialists in France.

      In 2008, the national Plan Alzheimer 2008 - 2012 had for objective to strengthen the
      search(research) on the Alzheimer's disease (MY) and for related disorders(confusions), to
      promote an early diagnosis and to improve at the same time the management of the patients and
      to support careers(quarries). A specific part(party) of this plan gave rise to the creation
      of the French national database Alzheimer ( BNA) to supply epidemiological data as well as
      indicators of activity. Since 2009 The information collected(taken in) in the BNA consists of
      a set(group) limited by data (CIMA of information minimum Corpus Alzheimer) concerning the
      demographic, clinical and diagnostic data defined by national consensus. The number of
      variables is limited to facilitate and to improve the participation in this national
      database. The participants are the Centers Report (CM)((LECTURE)) and Center Memory(Report)
      of Resources and Search(Research) (CMRR) and independent specialists. In 2015 more than 500
      Centers send CIMA to the BNA.

      The plan Disease Neurodegenerative 2014 - 2019 wishes to pursue and to amplify the BNA.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2009</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Actual">January 1, 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of the morbi-mortality</measure>
    <time_frame>16 years</time_frame>
    <description>number of people suffering from a disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evolution of the morbi-mortality</measure>
    <time_frame>16 years</time_frame>
    <description>number of deaths</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of the miscellaneous determiners of Access to healthcare or diagnosis</measure>
    <time_frame>16 years</time_frame>
    <description>number of the determiners of the access to healthcare and diagnosis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>New therapeutic plans</measure>
    <time_frame>16 years</time_frame>
    <description>Participate in the evaluation of new therapeutic plans of care</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Alzheimer desease and related disorders</arm_group_label>
    <description>Alzheimer desease and related disorders</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non ontervention / observational study</intervention_name>
    <description>non intervention</description>
    <arm_group_label>Alzheimer desease and related disorders</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Alzheimer desease and related disorders patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients consulting in French Memory Centres

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philippe ROBERT, PUPH</last_name>
    <phone>33492034773</phone>
    <email>robert.p@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aurelie MOUTON, PH</last_name>
    <phone>33492034773</phone>
    <email>mouton.a2@chu-nice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nice University Hospital</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe ROBERT, PUPH</last_name>
      <phone>33492034773</phone>
      <email>robert.p@chu-nice.fr</email>
    </contact>
    <contact_backup>
      <last_name>Aurelie MOUTON, PH</last_name>
      <phone>33492034773</phone>
      <email>mouton.a2@chu-nice.fr</email>
    </contact_backup>
    <investigator>
      <last_name>philippe ROBERT, PUPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>September 25, 2018</last_update_submitted>
  <last_update_submitted_qc>September 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

